HCVguidelines.org recently released a new section, “When and in Whom to Initiate HCV Therapy.” The website was developed by IDSA and The American Association for the Study of Liver Disease (AASLD) in collaboration with the International Antiviral Society-USA (IAS-USA) to assist clinicians treating patients with hepatitis C virus (HCV).With the addition of the new section, www.hcvguidelines.org now offers clinicians information on how to prioritize treatment for those patients who will derive the most benefit or will have the greatest impact on limiting further HCV transmission. According to the guidance, highest priority should be given to patients with advanced fibrosis with compensated cirrhosis and liver transplant recipients and high priority given to patients at high risk for liver-related complications and severe extra-hepatic HCV complications. The guidance provides further detailed information on additional conditions that warrant prioritization of treatment.
The website, developed by a panel of 27 liver disease and infectious diseases specialists and a patient advocate, provides recommendations based on the latest evidence and on consensus of the panelists. It is updated regularly to keep pace with improved diagnostic tools and new drug options as they become available.
“The benefits of curing HCV are clear from the standpoint of individual patients as well as that of the health and welfare of our society. This new guidance will help clinicians determine the best course of therapy for each patient given their unique condition,” said Barbara Murray, MD, FIDSA, president of IDSA.
The three organizations will continue to work together to provide future sections of the guidance website as well as timely updates. Upcoming sections will cover monitoring patients following treatment and management of acute HCV infection.
< Previous Article | Next Article >